Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Gastroenterology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Value-Based Care

Latest News

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge support and care coordination. | Image credit: @Prostock-studio-adobe.stock.jpeg

Long-Term Burdens for SJS/TEN Survivors Highlight Critical Care Gaps

By Sabrina McCrear

November 20th 2025

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.

Herbal supplements linked to lower autoantibody rates in dermatomyositis, suggesting alternative immune activation. | Image Credit: @PhotobyTawat-AdobeStock.jpeg

Herbal Use Linked to Lower Autoantibodies in Dermatomyositis

By Sabrina McCrear

November 19th 2025

New research links seborrheic dermatitis to a wide range of epithelial barrier diseases, highlighting the need for earlier detection and integrated care. | Image Credit: @cunaplus-adobe.stockjpeg

Seborrheic Dermatitis Linked to Higher Risk of Epithelial Barrier Diseases

By Sabrina McCrear

November 19th 2025

New analysis exposes ethical and access disparities for FDA-approved drugs in low-income regions. | Image Credit: @syahrir-stock.adobe.peg

Global Gaps in Drug Access After FDA Approval: Insights From New Study and Ethics Guidelines

By Sabrina McCrear

November 18th 2025

AI and digital health are redefining what’s possible in breast cancer treatment. | Image Credit: @PajarosVolando-adobe.stock.jpeg

5 AI and Digital Health Advances Transforming Breast Cancer Care and Research

By Sabrina McCrear

November 14th 2025

More News

The Success of California's ACO Model

A blog on Health Affairs highlights California's successful ACO models that are steadily moving towards the goal of 60% of the population being cared-for by an integrated healthcare delivery system.

Read More

Experts Discuss Medicare's New Oncology Care Model

Surabhi Dangi-Garimella, PhD

The American Journal of Managed Care convened experts in health policy, from health plans, and from community oncology, to discuss OCM and other issues in oncology care during the Oncology Stakeholders Summit, Spring 2015 Peer Exchange.

Read More

The Healthcare System Future

The Healthcare System Future

Watch

Actuarial Considerations in Consumer-Directed Healthcare

Actuarial Considerations in Consumer-Directed Healthcare

Watch

High-Deductible Health Plans

High-Deductible Health Plans

Watch

Exchange Marketplaces and Narrow Networks

Exchange Marketplaces and Narrow Networks

Watch

Risk in Pharmaceutical Budgeting

Risk in Pharmaceutical Budgeting

Watch

Sustainable Growth Rate Reform

Sustainable Growth Rate Reform

Watch

Accountable Care Organizations and Risk

Accountable Care Organizations and Risk

Watch

Medicaid Expansion

Medicaid Expansion

Watch

Coordination of Patient Care in and out of ACOs

Coordination of Patient Care in and out of ACOs

Watch

Variations and Consolidations of New Healthcare Delivery Systems

Variations and Consolidations of New Healthcare Delivery Systems

Watch

Innovative Healthcare Delivery Models

Innovative Healthcare Delivery Models

Watch

Healthcare Pricing Transparency Results

Healthcare Pricing Transparency Results

Watch

Pricing Transparency Tools for the Consumer and the Provider

Pricing Transparency Tools for the Consumer and the Provider

Watch

Healthcare Pricing Transparency

Healthcare Pricing Transparency

Watch

The Evidence Supporting VBP in Health Reform

The Evidence Supporting VBP in Health Reform

Watch

Feeding Back Value-Based Performance Information to Physicians

Feeding Back Value-Based Performance Information to Physicians

Watch

Comparing State Versus Private-Employer-Run Value-Based Purchasing

Comparing State Versus Private-Employer-Run Value-Based Purchasing

Watch

Introduction: Value-Based Purchasing in Healthcare Reform

Introduction: Value-Based Purchasing in Healthcare Reform

Watch

Appropriate, Value-Based Care in Immuno-Oncology

Appropriate, Value-Based Care in Immuno-Oncology

Watch

The Cost of Care in Immuno-Oncology

The Cost of Care in Immuno-Oncology

Watch

Measuring Response With Immuno-Oncology Agents in NSCLC

Measuring Response With Immuno-Oncology Agents in NSCLC

Watch

Integrating Immunotherapy in Lung Cancer

Integrating Immunotherapy in Lung Cancer

Watch

Targeted Therapies and the Sequencing of Immuno-Oncology Drugs

Targeted Therapies and the Sequencing of Immuno-Oncology Drugs

Watch

The Rationale for Initiating Therapy with an Immuno-Oncology Drug

The Rationale for Initiating Therapy with an Immuno-Oncology Drug

Watch

Anti-PD-1 Agents as Frontline Therapy

Anti-PD-1 Agents as Frontline Therapy

Watch

Anti-PD-1 Treatment Selection

Anti-PD-1 Treatment Selection

Watch

Considerations When Switching Therapy

Considerations When Switching Therapy

Watch

Determining Appropriate Duration of Treatment

Determining Appropriate Duration of Treatment

Watch

...

27 28 29 30 31 32 33 34 35

...

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences
AJMC®
All rights reserved.